The new agreement will allow Xtant to enter the cellular bone graft market which the company said is estimated to be between $252 million in 2015 and $400 million in 2019.
“Vivex is enthusiastic about teaming up with Xtant Medical, a leading distributor of biologics products. Working closely with leading biologics distributors like Xtant Medical helps further our mission of enhancing patient care by expanding industry knowledge and capability,” Vivex CEO Tracy Anderson said in a press release.
Canadian Xtant Medical said Vivex’s proprietary process preserves cell population including marrow-isolated adult multilineage inducible cells, which the company says supports the patients innate bone healing process.
“We are pleased to be adding this distinguished viable cell allograft to our biologic portfolio. The addition of OsteoVive will allow us to better meet the preferences of our surgeons, and will increase the value we are able to deliver to our customers,” Xtant CEO Dan Goldberger said in prepared remarks.
Earlier this month, Xtant said it won CE Mark approval in the European Union for its Aranax cervical plating system and and Irix-A stand alone anterior lumbar fusion device.
The company’s Aranax cervical plating system is distributed as a pre-stereilized, ready-to-use implant. The Irix-A stand alone anterior lumbar fusion device consists of an integrated titanium ring in a PEEK shell.